DK1326832T3 - Kemiske forbindelser - Google Patents

Kemiske forbindelser

Info

Publication number
DK1326832T3
DK1326832T3 DK01976453T DK01976453T DK1326832T3 DK 1326832 T3 DK1326832 T3 DK 1326832T3 DK 01976453 T DK01976453 T DK 01976453T DK 01976453 T DK01976453 T DK 01976453T DK 1326832 T3 DK1326832 T3 DK 1326832T3
Authority
DK
Denmark
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Application number
DK01976453T
Other languages
Danish (da)
English (en)
Inventor
Giuseppe Alvaro
Fabio Romano Di
Paolo Maragni
Marsia Tampieri
Maria Tranquillini
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1326832T3 publication Critical patent/DK1326832T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK01976453T 2000-10-17 2001-10-12 Kemiske forbindelser DK1326832T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0025354.2A GB0025354D0 (en) 2000-10-17 2000-10-17 Chemical compounds
PCT/GB2001/004580 WO2002032867A1 (en) 2000-10-17 2001-10-12 Chemical compounds

Publications (1)

Publication Number Publication Date
DK1326832T3 true DK1326832T3 (da) 2005-01-31

Family

ID=9901397

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01976453T DK1326832T3 (da) 2000-10-17 2001-10-12 Kemiske forbindelser
DK04077714T DK1524266T3 (da) 2000-10-17 2001-10-12 Farmaceutisk sammensætning

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04077714T DK1524266T3 (da) 2000-10-17 2001-10-12 Farmaceutisk sammensætning

Country Status (29)

Country Link
US (5) US7119092B2 (cs)
EP (4) EP1752449A1 (cs)
JP (1) JP3940359B2 (cs)
KR (1) KR100847414B1 (cs)
CN (1) CN1231468C (cs)
AR (1) AR034268A1 (cs)
AT (3) ATE278669T1 (cs)
AU (4) AU2001295723B2 (cs)
BR (1) BR0114637A (cs)
CA (1) CA2425876C (cs)
CY (1) CY1107634T1 (cs)
CZ (1) CZ299824B6 (cs)
DE (3) DE60142197D1 (cs)
DK (2) DK1326832T3 (cs)
ES (3) ES2282794T3 (cs)
GB (1) GB0025354D0 (cs)
HK (2) HK1058788A1 (cs)
HU (1) HU228146B1 (cs)
IL (3) IL155165A0 (cs)
MX (1) MXPA03003536A (cs)
MY (1) MY124957A (cs)
NO (1) NO324468B1 (cs)
NZ (1) NZ525091A (cs)
PL (1) PL203071B1 (cs)
PT (2) PT1524266E (cs)
SI (2) SI1326832T1 (cs)
TW (1) TWI299730B (cs)
WO (1) WO2002032867A1 (cs)
ZA (1) ZA200302801B (cs)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0108595D0 (en) 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US7482365B2 (en) 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
TWI283241B (en) * 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
JP4079727B2 (ja) * 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
ATE400568T1 (de) * 2002-12-23 2008-07-15 Janssen Pharmaceutica Nv Substituierte 4-(4-piperidin-yl-piperazin-1-yl)- azepan-derivate und ihre verwendung als tachykinin-antagonisten
JO2485B1 (en) * 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
ATE354572T1 (de) * 2002-12-23 2007-03-15 Janssen Pharmaceutica Nv Substituierte 1-piperidin-4-yl-4-azetidin-3-yl- piperazinderivate und deren verwendung als neurokininantagonisten
WO2004067093A2 (en) * 2003-01-27 2004-08-12 Glaxo Group Limited Nk1 receptor antagonists for the treatment of functional dyspepsia
FR2853648B1 (fr) * 2003-04-11 2006-08-18 Fournier Lab Sa Nouveaux derives de benzenesulfonamides et leur utilisation en therapeutique
WO2004087654A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
WO2004087685A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
WO2004089901A2 (en) * 2003-03-31 2004-10-21 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
WO2004110451A1 (en) * 2003-06-10 2004-12-23 Janssen Pharmaceutica N.V. Combinations for opioid-based treatment of pain comprising 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
BRPI0410630A (pt) * 2003-06-19 2006-06-13 Pfizer Prod Inc antagonista de nk1
JO2525B1 (en) * 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
WO2006062110A1 (ja) * 2004-12-06 2006-06-15 Banyu Pharmaceutical Co., Ltd. ピペラジン誘導体
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
BRPI0608847A2 (pt) 2005-03-08 2010-02-02 Janssen Pharmaceutica Nv derivados de diaza-espiro-[4,4]-nonano substituìdos e seu uso como antagonistas de neurocinina
GB0514707D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds
GB0514704D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds
GB0514705D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds
JP4904945B2 (ja) 2006-06-30 2012-03-28 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体の製造方法
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CA2698808A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
GB0812849D0 (en) * 2008-07-14 2008-08-20 Glaxo Wellcome Mfg Pte Ltd Novel compounds
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
EP2817312B1 (en) 2012-02-22 2016-02-17 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds
WO2015024203A1 (en) * 2013-08-20 2015-02-26 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds ii
MA51658A (fr) 2017-04-10 2020-12-02 Chase Therapeutics Corp Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies
EP3645120A4 (en) 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION
CN111116514B (zh) * 2020-01-10 2024-03-19 广州科锐特生物科技有限公司 一种1-环丙甲酰基哌嗪盐酸盐的制备方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536020A (en) * 1894-04-09 1895-03-19 Washing or bathing apparatus
US4327097A (en) 1974-05-09 1982-04-27 Toyama Chemical Co., Ltd. Novel penicillins
US4410522A (en) 1974-05-09 1983-10-18 Toyama Chemical Co., Ltd. Cephalosporins
US4379152A (en) 1974-05-09 1983-04-05 Toyama Chemical Co., Ltd. Cephalosporins
US4112090A (en) 1974-05-09 1978-09-05 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4219554A (en) 1974-05-09 1980-08-26 Toyama Chemical Company, Limited Novel penicillins and cephalosporins and process for producing same
US4110327A (en) 1974-05-09 1978-08-29 Toyama Chemical Co., Ltd. 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4087424A (en) 1974-05-09 1978-05-02 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
NO154582C (no) 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
JPS57118587A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel penicillin
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
GB8709666D0 (en) 1987-04-23 1987-05-28 Beecham Group Plc Compounds
GB8713061D0 (en) 1987-06-04 1987-07-08 Beecham Group Plc Compounds
US5109014A (en) 1990-12-10 1992-04-28 Jacobson Richard M N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
ES2149767T5 (es) 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
US5334387A (en) * 1993-02-23 1994-08-02 Colgate-Palmolive Company Topical composition comprising mono and dialkyl phosphates with a cosurfactant
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
DE59308873D1 (de) 1993-11-26 1998-09-17 Rockwool Mineralwolle Verfahren zum Herstellen einer Schmelze für die Mineralfaserherstellung
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
EP0721941A4 (en) 1994-07-15 1996-09-25 Meiji Seika Co NOVEL COMPOUNDS HAVING AN INHIBITING EFFECT ON PLATELET AGGREGATION
WO1996003378A1 (fr) 1994-07-26 1996-02-08 Sankyo Company, Limited Derives d'amide n-phenyle et d'uree
DE19520499C2 (de) 1994-09-17 2003-06-18 Boehringer Ingelheim Kg Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung
US5696123A (en) 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists
CA2198382A1 (en) 1994-09-30 1996-04-11 Novartis Ag 1-acyl-4-aliphatylaminopiperidine compounds
US5998444A (en) 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
EE9700141A (et) 1994-12-23 1997-12-15 Dr. Karl Thomae Gmbh Piperasiinderivaadid, neid sisaldavad ravimid, nende kasutamine ja valmistamise meetod
US5700801A (en) 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
DE19608665A1 (de) 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6057323A (en) 1996-03-08 2000-05-02 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036592A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507582A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシルプロテイントランスフェラーゼの阻害剤
CA2249604A1 (en) 1996-04-03 1997-10-09 Theresa M. Williams Inhibitors of farnesyl-protein transferase
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929077A (en) 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
WO1998024443A1 (en) 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating bipolar disorders
US5977104A (en) 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
US6114315A (en) 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
AU741725B2 (en) 1997-08-27 2001-12-06 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CA2309341A1 (en) 1997-11-24 1999-06-03 Merck & Co., Inc. Substituted .beta.-alanine derivatives as cell adhesion inhibitors
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
US6253732B1 (en) * 1999-11-11 2001-07-03 Ford Global Technologies, Inc. Electronic throttle return mechanism with a two-spring and two-lever default mechanism
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

Also Published As

Publication number Publication date
DE60127002T2 (de) 2007-10-31
AU2009201407A1 (en) 2009-05-07
MXPA03003536A (es) 2003-08-07
ATE468324T1 (de) 2010-06-15
PT1524266E (pt) 2007-05-31
DK1524266T3 (da) 2007-06-25
AU2005204234A1 (en) 2005-09-15
AU2005204234B2 (en) 2009-05-07
CA2425876A1 (en) 2002-04-25
KR100847414B1 (ko) 2008-07-18
US20040014770A1 (en) 2004-01-22
CN1483025A (zh) 2004-03-17
NO324468B1 (no) 2007-10-22
HU228146B1 (en) 2012-12-28
AU9572301A (en) 2002-04-29
PT1326832E (pt) 2005-01-31
US20060142302A1 (en) 2006-06-29
DE60142197D1 (de) 2010-07-01
IL155165A (en) 2008-11-26
ES2346108T3 (es) 2010-10-08
WO2002032867A1 (en) 2002-04-25
EP1326832B1 (en) 2004-10-06
PL361180A1 (en) 2004-09-20
KR20030036932A (ko) 2003-05-09
US7648990B2 (en) 2010-01-19
NZ525091A (en) 2005-04-29
DE60106287D1 (de) 2004-11-11
HK1075889A1 (en) 2005-12-30
HUP0301459A2 (en) 2006-09-28
CZ299824B6 (cs) 2008-12-03
DE60106287T2 (de) 2006-02-23
CZ20031082A3 (cs) 2004-08-18
JP2004511544A (ja) 2004-04-15
GB0025354D0 (en) 2000-11-29
HK1058788A1 (en) 2004-06-04
EP1921064A1 (en) 2008-05-14
EP1921064B1 (en) 2010-05-19
EP1752449A1 (en) 2007-02-14
ATE278669T1 (de) 2004-10-15
NO20031561L (no) 2003-06-14
IL155165A0 (en) 2003-10-31
AU2001295723B2 (en) 2005-05-26
CY1107634T1 (el) 2013-04-18
EP1524266B1 (en) 2007-02-28
CN1231468C (zh) 2005-12-14
AU2009201407B2 (en) 2011-12-15
ES2282794T3 (es) 2007-10-16
US7119092B2 (en) 2006-10-10
ZA200302801B (en) 2004-04-21
US7060702B2 (en) 2006-06-13
HUP0301459A3 (en) 2007-11-28
SI1326832T1 (en) 2005-02-28
AR034268A1 (es) 2004-02-18
ATE355271T1 (de) 2006-03-15
CA2425876C (en) 2009-07-07
US20050137208A1 (en) 2005-06-23
US20100081667A1 (en) 2010-04-01
PL203071B1 (pl) 2009-08-31
IL191486A0 (en) 2008-11-03
DE60127002D1 (de) 2007-04-12
NO20031561D0 (no) 2003-04-07
BR0114637A (pt) 2003-09-30
MY124957A (en) 2006-07-31
EP1524266A1 (en) 2005-04-20
US7294630B2 (en) 2007-11-13
EP1326832A1 (en) 2003-07-16
JP3940359B2 (ja) 2007-07-04
TWI299730B (en) 2008-08-11
US20080021041A1 (en) 2008-01-24
ES2227287T3 (es) 2005-04-01
SI1524266T1 (sl) 2007-08-31

Similar Documents

Publication Publication Date Title
AR028414A1 (es) Compuestos quimicos
DK1326832T3 (da) Kemiske forbindelser
AR028605A1 (es) Compuesto quimico
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
NO20021637L (no) Kjemikalske forbindelser
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
NO20024774D0 (no) Kjemiske forbindelser
NO20032829L (no) Kjemiske forbindelser
AR027983A1 (es) Novedosos compuestos
NO20030628L (no) Kjemiske forbindelser
IS6657A (is) Ný efnasambönd
ATE372338T1 (de) Deshalogenverbindungen
AR028220A1 (es) Novedosos compuestos
NO20030303L (no) Kalsilytiske forbindelser
NO20031837D0 (no) Kalsilytiske forbindelser
NO20023508L (no) Kalsilyttiske forbindelser
AR028399A1 (es) Nuevos compuestos
AR028304A1 (es) Compuestos quimicos
SE0003664D0 (sv) Chemical compounds
SE0004925D0 (sv) Kemiska föreningar
SE0103797D0 (sv) Chemical compounds
SE0003477D0 (sv) Compounds
SE0002788D0 (sv) New compounds
SE0000263D0 (sv) New compounds
IS8579A (is) Ný efnasambönd